According to HMA indication, the ORR was respectively 69% (11/16) and 36% (9/25) for patients who received HMA as frontline therapy or for R/R CBF-AML (Chi-squared test, p = 0.041). The gene discussed is CEBPZ; the disease is acute myeloid leukemia.